

## Syndax Announces Participation at Three Upcoming Investor Conferences

September 2, 2020

WALTHAM, Mass., Sept. 2, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in three upcoming virtual investor conferences. The details for the three conferences are:

- Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020. Panel at 11:40 a.m. ET.
- Baird 2020 Virtual Global Healthcare Conference on Thursday, September 10, 2020. Fireside chat at 4:20 p.m. ET.
- Morgan Stanley 18th Annual Global Virtual Healthcare Conference on Monday, September 14, 2020. Fireside chat at 2:15 p.m. ET.

A live webcast of the events can be accessed from the Investor section of the Company's website at <a href="www.syndax.com">www.syndax.com</a>, where a replay of the event will also be available for a limited time.

## About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit <a href="www.syndax.com">www.syndax.com</a> or follow the Company on <a href="www.syndax.com">Twitter</a> and <a href="www.syndax.com">LinkedIn</a>.

## **Syndax Contacts**

Investor Contact Melissa Forst Argot Partners melissa@argotpartners.com Tel 212.600.1902

Media Contact Ted Held ted.held@gcihealth.com Tel 212.798.9842

## SNDX-G

C View original content: <a href="http://www.prnewswire.com/news-releases/syndax-announces-participation-at-three-upcoming-investor-conferences-301122452.html">http://www.prnewswire.com/news-releases/syndax-announces-participation-at-three-upcoming-investor-conferences-301122452.html</a>

SOURCE Syndax Pharmaceuticals, Inc.